Company Overview
About Selkirk Pharma
Selkirk Pharma is a contract development and manufacturing organization (CDMO) founded in 2018 by fill/finish industry veterans and headquartered in Spokane, Washington. The company was purpose-built to address the domestic shortage of aseptic fill/finish manufacturing capacity for sterile injectable drug products — a segment critical to biologics, small molecules, and parenteral medicines. Its 115,000-square-foot GMP facility at the Pacific Northwest Technology Park operates with advanced isolator technology from SKAN, Bausch and Strobel VarioSys dose-filling systems, and single-use systems designed to meet both US FDA and EU Annex 1 compliance standards.
Business Model & Competitive Advantage
Selkirk has raised over $82 million in total funding across multiple rounds, supporting facility build-out, technology upgrades, and capacity expansion. The company has outlined plans for a $90 million second factory to bring additional injectable drug manufacturing capacity onshore — a strategic priority amplified by US government efforts to onshore pharmaceutical manufacturing. In February 2025, Selkirk launched ClinFAST, a proprietary program designed to fast-track fill/finish manufacturing for clinical trial materials, reducing lead times for drug developers in early and mid-stage clinical development.
Competitive Landscape 2025–2026
Selkirk''s service offering covers the full fill/finish lifecycle: formulation development, analytical testing, aseptic filling (vials, syringes, cartridges), manual product inspection, packaging, and logistics. Its client base spans small biotechs developing novel therapeutics to larger pharmaceutical companies seeking domestic manufacturing redundancy. The CDMO competes with established players including Catalent, Lonza, and Patheon, while differentiating on its US-based, high-compliance, modern facility infrastructure and speed-to-clinic capabilities.
Frequently Asked Questions
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare Selkirk Pharma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Selkirk Pharma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Selkirk Pharma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Selkirk Pharma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →